Pharma Sources Insight第十一期：2024全球制药行业前瞻

热门推荐： Pharma Sources Insight , Sickle Cell Disease Patients , Gene Therapy ,

来源：CPHI制药在线

2024-01-16

Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the pharma industry, from China to the world.

扫描二维码开始阅读

Scan to preview the contents.

https://flbook.com.cn/c/eWk2A8AsPG

Pharma Sources Insight January 2024 focuses on the following topics:

SPONSORED BY

- XINJITAI PHARMA PACKAGING

FROM THE EDITOR

- Hope for Sickle Cell Disease Patients as Gene Therapy Gets More Approvals

GLOBAL PHARMA INDUSTRY

- Global Pharmaceutical Companies' Dream of Nuclear Medicine

- Personalized Medicine: A New Era in Healthcare

- New regulations in the Year 2023 for Different Regulatory Bodies Around the World

NEW DRUG R&D

- Global R&D Drug Development 2023: Overcoming Barriers, Bringing Hope to Patients and ESG focused

Worth Reading:

-Advancements in scientific technologies to Drug discovery and Development 2023

-What To Expect In The 2024 Pharmaceutical Market

- The Evolving Landscape of Heart Failure Therapies

PHARMA IN CHINA

- Looking at the New Layout of MNC in China from AstraZeneca Joining Hands with Chinese Pharmaceutical Companies Again

- Popular Products and Companies at PharmaSources.com

INDUSTRY INSIGHT

- Flexible Production in the Pharmaceutical Industry: Navigating the Dynamics of Innovation

- Case Study of FDA Warning Letters

About Pharma Sources Insight

Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the pharma industry, from China to the world. It follows up new developments with the leading drug-manufacturers in China which further affect the world.

Now, join PharmaSources.com to get access to news of the Chinese pharmaceutical enterprises and to witness industrial changes through the exclusive perspectives of our expert writers into crucial aspects of the pharmaceutical field, all under PharmaSources.com and CPhI China.

【往期回顾】

点击下图，免费阅读往期内容